Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models
Rattachement africain : ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid proliferation of clinics/programs offering a variety of ketamine based treatments. A quick glance at the existing evidence, however, reveals a confusing scenario for patients, healthcare providers, and regulators. Overall, there are no standard definitions of what constitutes a psychotherapeutic intervention within a psychedelic-based or a ketamine-based treatment. More specifically, studies have not always distinguished between using a well-known, manualized psychotherapy, providing psychoeducation and psychological support, or providing a therapy specifically to integrate the drug experience in psychedelic trials. Also, it is difficult to determine the role of the psychedelic agent as a stand-alone treatment, and the relative importance (if any) of the psychedelic experience for the desired therapeutic effect. In this perspective, we discuss the evolving landscape of psychedelic-based and ketamine-based treatments, highlighting different therapeutic models, their methodologies, and the need for clearer definitions and rigorous clinical trials. The document proposes three new definitions to improve clarity in evaluating the effects of these agents and the role of psychotherapies. We suggest language that will distinguish: (1) when the drug is used for its pharmacologic effects as a stand-alone treatment, without requiring the psychedelic experience or combined psychotherapy; (2) when the treatment requires the acute psychological effects of the drug to assist psychotherapy and (3) When ketamine or a psychedelic agent is used in combination with a structured, manualized psychotherapy that could be implemented even in the absence of these agents. We hope that this new terminology and definitions will help distinguish the various therapeutic roles of these agents (as stand-alone treatments or in combination with psychotherapies), and facilitate study designs, regulatory pathways, and more informed patient care.Plain Language Summary TitleKetamine, Psychedelics, and Psychotherapy: Understanding treatment models to better inform practice.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models
- Date Crossref
- 28/10/2025
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Alberta Neuroscience and Mental Health Institute pays non établi dans la noticeUniversité ou école supérieure
-
Women and Children’s Health Research Institute pays non établi dans la noticeStructure de recherche
-
Neuroscience and Mental Health Institute pays non établi dans la noticeStructure de recherche
-
Providence Health Care pays non établi dans la noticeÉtablissement de santé
-
Queen's University Centre for Psychedelics Health and Research pays non établi dans la noticeUniversité ou école supérieure
-
Kingston Health Sciences Centre pays non établi dans la noticeÉtablissement de santé
-
Providence Care Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Toronto Department of Pharmacology pays non établi dans la noticeUniversité ou école supérieure
Neuroscience and Mental Health Institute — University of Alberta, Women and Children’s Health Research Institute et Neuroscience and Mental Health Institute, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.